Literature DB >> 10928970

Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.

K Yamaguchi1, K Motegi, Y Iwakura, Y Endo.   

Abstract

Aminobisphosphonates (aminoBPs) are potent inhibitors of bone resorption. However, they cause undesirable inflammatory reactions, including fever, in humans. Intraperitoneal injection of aminoBPs into mice also induces inflammatory reactions, including a prolonged elevation of the activity of the histamine-forming enzyme, histidine decarboxylase (HDC). Because interleukin-1 (IL-1) is a typical pyrogen and a strong inducer of HDC, we examined whether aminoBPs induce inflammatory reactions in mice deficient in genes for both IL-1alpha and IL-1beta (IL-1-KO mice). In control mice, aminoBPs induced an elevation of HDC activity and other inflammatory reactions (enlargement of the spleen, atrophy of the thymus, exudate in the thorax and increase in granulocytic cells in the peritoneal cavity). These responses were all weak or undetectable in IL-1-KO mice. We have previously shown that lipopolysaccharides (LPSs) from Escherichia coli and Prevotella intermedia (a prevalent gram-negative bacterium both in periodontitis and endodontal infections) are capable of inducing HDC activity in various tissues in mice. In control mice treated with an aminoBP, the LPS-induced elevations of serum IL-1 (alpha and beta) and tissue HDC activity were both markedly augmented. However, such an augmentation of HDC activity was small or undetectable in IL-1-KO mice. These results, taken together with our previous findings (i) suggest that IL-1 is involved in the aminoBP-induced inflammatory reactions and (ii) lead us to think that under some conditions, inflammatory reactions induced by gram-negative bacteria might be augmented in patients treated with an aminoBP. In this study, we also obtained a result suggesting that IL-1-deficiency might be compensated by a second, unidentified, mechanism serving to induce HDC in response to LPS when IL-1 is lacking.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928970      PMCID: PMC1572219          DOI: 10.1038/sj.bjp.0703460

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  68 in total

Review 1.  Geranylgeranylated proteins.

Authors:  J A Glomset; M H Gelb; C C Farnsworth
Journal:  Biochem Soc Trans       Date:  1992-05       Impact factor: 5.407

2.  Cellular and molecular changes accompanying the progression from insulitis to diabetes.

Authors:  I André-Schmutz; C Hindelang; C Benoist; D Mathis
Journal:  Eur J Immunol       Date:  1999-01       Impact factor: 5.532

3.  Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.

Authors:  H L Benford; J C Frith; S Auriola; J Mönkkönen; M J Rogers
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

4.  Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.

Authors:  Y Endo; M Shibazaki; K Yamaguchi; M Nakamura; H Kosugi
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.

Authors:  E van beek; C Löwik; G van der Pluijm; S Papapoulos
Journal:  J Bone Miner Res       Date:  1999-05       Impact factor: 6.741

6.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

Authors:  E van Beek; E Pieterman; L Cohen; C Löwik; S Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

7.  1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.

Authors:  D Amin; S A Cornell; M H Perrone; G E Bilder
Journal:  Arzneimittelforschung       Date:  1996-08

8.  Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

Authors:  E van Beek; E Pieterman; L Cohen; C Löwik; S Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1999-02-16       Impact factor: 3.575

9.  Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.

Authors:  M B Martin; W Arnold; H T Heath; J A Urbina; E Oldfield
Journal:  Biochem Biophys Res Commun       Date:  1999-10-05       Impact factor: 3.575

10.  Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

Authors:  A Sauty; M Pecherstorfer; I Zimmer-Roth; P Fioroni; L Juillerat; M Markert; H Ludwig; P Leuenberger; P Burckhardt; D Thiebaud
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

View more
  9 in total

1.  Primary role of interleukin-1 alpha and interleukin-1 beta in lipopolysaccharide-induced hypoglycemia in mice.

Authors:  Senri Oguri; Katsutoshi Motegi; Yoichiro Iwakura; Yasuo Endo
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1.

Authors:  John T Norton; Tomoko Hayashi; Brian Crain; John S Cho; Lloyd S Miller; Maripat Corr; Dennis A Carson
Journal:  J Immunol       Date:  2012-03-02       Impact factor: 5.422

3.  Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates.

Authors:  John T Norton; Tomoko Hayashi; Brian Crain; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

4.  Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Authors:  Ágnes Janovszky; Andrea Szabó; Renáta Varga; Dénes Garab; Mihály Boros; Csilla Mester; Nikolett Beretka; Tamás Zombori; Hans-Peter Wiesmann; Ricardo Bernhardt; Imre Ocsovszki; Péter Balázs; József Piffkó
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

5.  Protective Effects of Simvastatin Against Alendronate-Induced Gastric Mucosal Injury in Rats.

Authors:  Nathalia S Carvalho; Mônica M Silva; Renan O Silva; Lucas A D Nicolau; Thiago S L Araújo; Douglas S Costa; Nayara A Sousa; Luan K M Souza; Pedro M G Soares; Jand Venes R Medeiros
Journal:  Dig Dis Sci       Date:  2015-09-24       Impact factor: 3.199

Review 6.  Clodronic acid formulations available in Europe and their use in osteoporosis: a review.

Authors:  Bruno Frediani; Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 7.  Clodronate news of efficacy in osteoporosis.

Authors:  Alfredo Nardi; Lorenzo Ventura; Luisella Cozzi; Greta Tonini
Journal:  Clin Cases Miner Bone Metab       Date:  2016-05-11

Review 8.  Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates.

Authors:  Maurizio Muratore; Eugenio Quarta; Antonella Grimaldi; Fabio Calcagnile; Laura Quarta
Journal:  Drug Des Devel Ther       Date:  2011-10-19       Impact factor: 4.162

9.  The hydrogen sulfide donor, Lawesson's reagent, prevents alendronate-induced gastric damage in rats.

Authors:  L A D Nicolau; R O Silva; S R B Damasceno; N S Carvalho; N R D Costa; K S Aragão; A L R Barbosa; P M G Soares; M H L P Souza; J V R Medeiros
Journal:  Braz J Med Biol Res       Date:  2013-08-16       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.